Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Embracer Group in connection with a EUR 600 million multicurrency revolving facility agreement
Mandate

Vinge has advised Embracer Group in connection with a EUR 600 million multicurrency revolving facility agreement

July 19, 2024 M&A

Vinge has advised Embracer Group in connection with a EUR 600 million multicurrency revolving facility agreement entered into with BNP Paribas, Citibank Europe, DNB, JP Morgan, Nordea, SEB and Swedbank.

Vinge has advised Embracer Group AB (publ) (“Embracer”) in connection with the entry into of a EUR 600 million financing agreement with BNP Paribas, Citibank Europe, DNB, JP Morgan, Nordea, SEB and Swedbank. Embracer is a global group of entrepreneurial businesses in the gaming and entertainment industry.

The new facility of EUR 600 million is used to refinance Embracer’s existing revolving credit facilities of SEK 4.8 billion. The terms and conditions for the new facility have been improved, including a notably lower credit margin for utilised debt, which will reduce interest expenses through both improved terms and a reduced financial leverage.

Vinge’s team consisted of Albert Wållgren, Felix Möller, Ida Redander and Josef Groow.

Related

Vinge advises OsteoCentric on the public offer for Integrum

 OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

 Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

 Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025